Welcome to our dedicated page for Polomar Health SEC filings (Ticker: PMHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Polomar Health Services, Inc. filings document a Nevada health-services operating company with disclosures centered on pharmaceutical product fulfillment and distribution arrangements. Form 8-K reports cover material definitive agreements, amendments and termination-related notices involving the marketing of the company's pharmaceutical products, prescription fulfillment responsibilities and related account-management services.
Registration statements and amendments describe securities registration activity, historical financial statements and capital-structure disclosures. Late-filing notices address annual and quarterly reporting timing, while periodic disclosure categories include operating and financial results and other corporate events reported under the Exchange Act.
Polomar Health Services, Inc. has registered up to 7,710,219 shares of common stock for resale by existing stockholders. The company will not receive any proceeds from these sales; all proceeds go to the selling stockholders, who may sell at a fixed price of $0.20 per share until any national exchange or OTCQX/OTCQQB listing, and thereafter at market prices. As of December 11, 2025, 28,053,090 shares of common stock were outstanding, and the stock last closed at $0.08 on the OTCID Basic Market.
Polomar operates a Florida-licensed specialty compounding pharmacy, focusing on dermatology, GLP‑1 weight loss drugs and men’s health, and holds a license to patent‑pending inhalable formulations such as sildenafil. It is a development-stage business with a history of losses, significant related‑party debt and substantial doubt about its ability to continue as a going concern without new financing. A pending merger with Altanine Inc. is expected, if completed, to leave Altanine holders owning about 80% of the combined company, subject to numerous conditions including a Nasdaq listing and a reverse stock split.
Polomar Health Services, Inc. disclosed a second amendment to its Amended and Restated Product Fulfillment and Distribution Agreement with ForHumanity, Inc. and Island Group 40, LLC. The initial exclusivity period is pushed back from March 31, 2025 to June 30, 2025, giving more time under the existing exclusive arrangement.
The Company gains a new right to terminate the agreement if specified minimum average monthly sales targets are not met between January 1, 2026 and July 31, 2026. Exclusivity can be extended through December 31, 2026 if the Company receives at least $1,750,000 in revenues from ForHumanity on or before June 30, 2026, and further through June 30, 2027 if total revenues from ForHumanity reach $5,000,000 for the calendar year ending December 31, 2026.
The payment schedule for remaining guaranteed amounts is revised to $100,000 on or before December 8, 2025, $200,000 on or before December 29, 2025, and $200,000 on or before January 12, 2026. Polomar notes it has already received $350,000 of the total $750,000 in guaranteed payments tied to this agreement.
Polomar Health Services, Inc. filed Amendment No. 2 to its Form S-1 registration statement, allowing a proposed public sale of its securities from time to time after the statement becomes effective. The amendment details estimated offering-related expenses of $30,000, including a Securities and Exchange Commission registration fee of $860.83, along with accounting, legal, and miscellaneous costs.
The company explains broad indemnification protections for its directors and officers under Nevada law and its bylaws, and notes that it maintains director and officer liability insurance. It also discloses recent unregistered issuances, including 10,000,000 shares of common stock issued on September 12, 2024 upon conversion of 500,000 shares of Series A preferred stock, and approximately 207,414,147 shares of common stock issued as of September 30, 2024 to former Polomar members in connection with an acquisition, all relying on Section 4(a)(2) of the Securities Act.
Polomar Health Services, Inc. has filed an amended Form S-1 to register up to 7,710,219 shares of common stock for resale by existing selling stockholders. The company will not receive any proceeds from these sales; all net proceeds go to the selling stockholders. Shares may be sold at a fixed price of $0.20 until an exchange or OTCQX/OTCQB listing, versus a recent OTCID Basic Market bid of $0.08 on December 5, 2025.
Polomar operates a licensed compounding pharmacy in Florida focused on dermatology, GLP‑1 weight‑loss drugs and erectile dysfunction therapies, and plans digital platforms such as SlimRx and PoloMeds. It relies on a licensed inhalable drug IP portfolio from Pinata Holdings and an exclusivity‑based fulfillment agreement with ForHumanity that includes a $750,000 guaranteed payment and revenue thresholds for extended exclusivity.
The business is development stage, with a history of losses, heavy related‑party debt at 12%+ rates, and going‑concern risks. A planned merger with Altanine would leave Altanine holders owning about 80% of the combined company, subject to audits, SEC and Nasdaq approvals, a reverse split to a $10.00 share price, and supermajority stockholder consent. The filing highlights regulatory, IP, financing, dilution and penny‑stock trading risks, as well as potential price pressure from selling stockholder resales.
Polomar Health Services (PMHS) reported a net loss of $1,712,193 for the nine months ended September 30, 2025, on revenue of $16,174, and disclosed substantial doubt about its ability to continue as a going concern. Cash was $38,854 with an accumulated deficit of $4,623,356 and a stockholders’ deficit of $7,766,596. Revenue fell sharply from $37,954 in the prior-year period while operating expenses, mainly general and administrative costs of $1,588,725, remained high. The business is being repositioned from local dermatology compounding to online fulfillment of GLP-1 and men’s health drugs and relies heavily on third-party telehealth platforms. To fund operations, the company entered into multiple related-party promissory notes and issued Series A Convertible Preferred Stock. It also signed a $750,000 guaranteed-payment ForHumanity licensing deal for inhalable drugs and agreed to an Altanine merger under which Altanine holders are expected to own about 80% of the combined company.
Polomar Health Services, Inc. filed a late notice for its Q3 2025 Form 10‑Q, citing unexpected delays in completing financial statements and stating it expects to file within five calendar days.
The company highlighted significant operational changes following its September 30, 2024 reverse recapitalization with Polomar Specialty Pharmacy and a shift from retail to wholesale. For the nine months ended September 30, 2025, revenue was approximately $16,174 versus $37,954 a year earlier, while operating expenses were approximately $1,618,886 versus $632,217. The company reported a net loss of approximately $1,712,194 compared with $622,544 in the prior period, reflecting higher legal, accounting, consulting, interest, and payroll costs.
Polomar Health Services, Inc. announced a First Amendment to its Agreement and Plan of Merger and Reorganization with Altanine Inc., updating the exchange terms for the planned combination. The amendment defines the “Exchange Ratio” as one share of Parent Common Stock for each share of Company Common Stock and five shares of Parent Preferred Stock for each share of Company Preferred Stock, subject to adjustment.
The amendment, dated October 8, 2025, applies to the merger among Polomar Health, its wholly owned subsidiary Polomar Merger Sub, Inc., and Altanine Inc. The company attached the full amendment as Exhibit 2.1 and incorporated it by reference.
Polomar Health Services (PMHS) insider buying disclosed on Form 4. Terrence M. Tierney, President and Director, reported three open-market purchases: 125,000 shares on 06/27/2025, 8,333 shares on 07/15/2025 and 7,695 shares on 08/15/2025, bringing his beneficial ownership to 141,028 shares. Reported aggregate cash amounts are shown for each lot on the form. The Form 4 is signed by the reporting person.
Polomar Health Services (PMHS) insider buying disclosed on Form 4. Terrence M. Tierney, President and Director, reported three open-market purchases: 125,000 shares on 06/27/2025, 8,333 shares on 07/15/2025 and 7,695 shares on 08/15/2025, bringing his beneficial ownership to 141,028 shares. Reported aggregate cash amounts are shown for each lot on the form. The Form 4 is signed by the reporting person.
Polomar Health Services, Inc. filed an S-1 describing a recent recapitalization, related-party financings, and material liquidity constraints. The company sold 90,437,591 common shares (about 83% of issued and outstanding) and 500,000 Series A preferred shares to CWR 1, LLC for $350,000. The former CEO and chairman resigned. The filing discloses multiple promissory notes and related-party advances including a Reprise Note with outstanding principal of $716,402.67 and accrued interest of $29,508.91 as of December 31, 2024 (amended and larger balances reported through June 30, 2025), a $150,000 CWR Note II with initial 12% APR and milestone draws, and other notes exchanged for preferred stock.
The company reported no cash equivalents, net loss of $1,341,333 for 2024, accumulated deficit of $2,911,163 as of December 31, 2024 (increased to $3,973,581 as of June 30, 2025), and explicit substantial doubt about its ability to continue as a going concern within one year.
Polomar Health Services, Inc. filed an S-1 describing a recent recapitalization, related-party financings, and material liquidity constraints. The company sold 90,437,591 common shares (about 83% of issued and outstanding) and 500,000 Series A preferred shares to CWR 1, LLC for $350,000. The former CEO and chairman resigned. The filing discloses multiple promissory notes and related-party advances including a Reprise Note with outstanding principal of $716,402.67 and accrued interest of $29,508.91 as of December 31, 2024 (amended and larger balances reported through June 30, 2025), a $150,000 CWR Note II with initial 12% APR and milestone draws, and other notes exchanged for preferred stock.
The company reported no cash equivalents, net loss of $1,341,333 for 2024, accumulated deficit of $2,911,163 as of December 31, 2024 (increased to $3,973,581 as of June 30, 2025), and explicit substantial doubt about its ability to continue as a going concern within one year.